Title: ANTI-NGF ANTIBODIES AND METHODS USING SAME

Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
   IPC: A61K 39/395 (2006.01)
   USPC: 424/141.1
   According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
   Minimum documentation searched (classification system followed by classification symbols)
   U.S.: 424/141.1
   Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

   Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
   Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>Hongo et al. (Hybridoma 19: 215-277 (2000), entire document, esp. Table 1, teaches 911 mAb, upon which Abs recited in the claims are based. Also teach using embryonic rat neurons, which is an obvious variant of embryonic mouse neurons, thus the claims lack inventive step.</td>
<td>1-5</td>
</tr>
<tr>
<td>Y</td>
<td>WO 93/06213 (MEDICAL RESEARCH COUNCIL--Hoogenboom et al.) 1 April 1993, entire document and abstract with figure, teaches how to make humanized antibodies, thus combined with the preceding reference, the claims lack inventive step.</td>
<td>1-5, 33</td>
</tr>
<tr>
<td>Y</td>
<td>WO 01/27160 (APPLIED MOLECULAR EVOLUTION, Inc.--Huse et al) 19 April 2001, entire document, teaches methods of optimizing antibody variable regions; methods can be employed to make variants over 911 mAb, upon which Abs recited in the claims are based, thus combined with preceding references, the claims lack inventive step.</td>
<td>1-33</td>
</tr>
</tbody>
</table>

Additional documents listed in the continuation of Box C.

See patent family annex.

Date of the actual completion of the international search
29 March 2006 (29.03.2006)

Date of mailing of the international search report
02 JUN 2006

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 272-3201

Authorized officer
Christina Borgeest
Telephone No. 571-272-1600

Form PCT/ISA/210 (second sheet) (July 1998)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>Aloe et al. Growth Factors 1993, 9: 249-155, see whole document, esp. p. 151, column 2, 2nd paragraph, teach method of treating rheumatoid arthritis using anti-NGF polyclonal antibody, but combined with previous references, the claims lack inventive step.</td>
<td>35-44</td>
</tr>
</tbody>
</table>
Continuation of B. FIELDS SEARCHED Item 3:
STN, WEST
search terms: anti-NGF or NGF antibody